OPTIRAY 320 Drug Patent Profile
When do Optiray 320 patents expire, and when can generic versions of Optiray 320 launch?
Optiray 320 is a drug marketed by Liebel-flarsheim and is included in two NDAs.
The generic ingredient in OPTIRAY 320 is ioversol. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OPTIRAY 320?
- What are the global sales for OPTIRAY 320?
- What is Average Wholesale Price for OPTIRAY 320?
Summary for OPTIRAY 320
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 77 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,623 |
| DailyMed Link: | OPTIRAY 320 at DailyMed |
Recent Clinical Trials for OPTIRAY 320
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke Clinical Research Institute | Phase 4 |
| GE Healthcare | Phase 4 |
| Bayer | Phase 4 |
Pharmacology for OPTIRAY 320
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OPTIRAY 320
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 320 | ioversol | INJECTABLE;INJECTION | 019710-001 | Dec 30, 1988 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Liebel-flarsheim | OPTIRAY 320 | ioversol | INJECTABLE;INJECTION | 020923-002 | May 29, 1998 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIRAY 320
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 320 | ioversol | INJECTABLE;INJECTION | 019710-001 | Dec 30, 1988 | ⤷ Start Trial | ⤷ Start Trial |
| Liebel-flarsheim | OPTIRAY 320 | ioversol | INJECTABLE;INJECTION | 020923-002 | May 29, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTIRAY 320
See the table below for patents covering OPTIRAY 320 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 552188 | ⤷ Start Trial | |
| Australia | 9151182 | ⤷ Start Trial | |
| Canada | 1198739 | DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE) | ⤷ Start Trial |
| Germany | 3362967 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIRAY 320
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0083964 | SPC/GB93/089 | United Kingdom | ⤷ Start Trial | SPC/GB93/089: 20041015 |
| 0083964 | 93C0142 | Belgium | ⤷ Start Trial | PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch